SEC Filing Summary: Nile Therapeutics, Inc. (8-K)
Business Context and Reporting Period
This Form 8-K was filed by Nile Therapeutics, Inc. on August 17, 2009, reporting events as of August 13, 2009. The filing serves to announce the company's financial results for the second quarter ended June 30, 2009. The registrant is incorporated in Delaware and maintains its principal executive offices in San Mateo, California.
Key Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. The document references a press release (Exhibit 99.1) containing these details but explicitly states that the exhibit and its information are "furnished" and not "filed" for purposes of Section 18 of the Exchange Act. Consequently, no financial metrics can be extracted directly from this text.
Material Changes
The filing does not contain data to compare current period performance against prior periods. The specific financial results and any material changes are contained within the referenced press release, which is not included in the provided text.
Guidance, Outlook, and Risks
The filing does not include management commentary, forward-looking guidance, risk factors, or contingencies. The document is a procedural notification of the issuance of a press release regarding Q2 2009 results.
Investor Verification Checklist
- Verify the specific Q2 2009 financial figures (revenue, net loss, cash position) by reviewing the press release dated August 13, 2009, referenced as Exhibit 99.1.
- Confirm the company's current cash runway and burn rate, as these are critical for a biotechnology firm but are not detailed in this 8-K text.
- Check for any subsequent filings or updates regarding the company's operational status post-August 2009.
- Note the discrepancy in the request metadata (Capricor Therapeutics) versus the filing content (Nile Therapeutics) and ensure the correct entity is being analyzed.